| Autor: |
van Burik, Jo-Anne H., Hare, Roberta S., Solomon, Howard F., Corrado, Michael L., Kontoyiannis, Dimitrios P. |
| Předmět: |
|
| Zdroj: |
Clinical Infectious Diseases; 4/1/2006, Vol. 42 Issue 7, pE61-E65, 5p |
| Abstrakt: |
To evaluate the activity of posaconazole for treatment of zygomycosis, a disease for which therapeutic options are limited, we conducted a retrospective study including 91 patients with zygomycosis (proven zygomycosis, 69 patients; probable zygomycosis, 22 patients). Patients had infection that was refractory to prior antifungal treatment (n = 81) or were np81 intolerant of such treatment (n = 10) and participated in the np10 compassionate-use posaconazole (800 mg/day) program. The rate of success (i.e., either complete or partial response) at 12 weeks after treatment initiation was 60%, and 21% of patients had stable disease. The overall high success and survival rates reported here provide encouraging data regarding posaconazole as an alternative therapy for zygomycosis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
